n-Dodecyl-β-d-Maltoside Inhibits Aggregation of Human Interferon-β-1b and Reduces Its Immunogenicity-Reference-Cited by-同舟云学术

n-Dodecyl-β-d-Maltoside Inhibits Aggregation of Human Interferon-β-1b and Reduces Its Immunogenicity

Published:2010-06-08 Issue:1 Volume:6 Page:158-162
ISSN:1557-1890
Container-title:Journal of Neuroimmune Pharmacology
language:en
Short-container-title:J Neuroimmune Pharmacol

Author:

Rifkin Robert A.,Maggio Edward T.,Dike Sonny,Kerr Douglas A.,Levy Michael

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Immunology,Immunology and Allergy,Neuroscience (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1007/s11481-010-9226-7.pdf

Reference25 articles.

1. Bayer HealthCare Pharmaceuticals Inc. (2007) Betaseron prescribing information. Bayer HealthCare Pharmaceuticals, Leverkusen, Germany

2. Biogen Idec Inc (2006) Avonex prescribing information. Biogen Idec, Cambridge

3. Bohidar HB (1998) Light scattering and viscosity study of heat aggregation of insulin. Biopolymers 45:1–8

4. Environmental Protection Agency (2005) Alkyl (C10–C16) polyglycosides; exemptions from the requirement of a tolerance. 40 CFR Part 180. 70 (177): 54281–54286

5. Fradkin AH, Carpenter JF, Randolph TW (2009) Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98:3247–3264

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer;Urothelial Carcinoma;2023

2. Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates;Pharmaceutics;2022-11-23

3. Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis;Journal of Controlled Release;2022-09

4. Computational Study Reveals PARP1 and P2Y1 Receptors as Prospective Targets of Withaferin-A for Cardiovascular Diseases;Letters in Drug Design & Discovery;2021-12-28

5. Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System;Drugs in R&D;2021-08-25